UBS Group’s Neurotrope, Inc. Common NTRP Stock Holding History

UBS Group’s Portfolio NTRP Stock Details NTRP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,000	Closed	-$11K	–	9098
2020 Q3	$11K	Buy	10,000 +8,551	+590%	+$9.84K	﹤0.01%	6822
2020 Q2	$2K	Sell	1,449 -5,180	-78%	-$6.49K	﹤0.01%	7707
2020 Q1	$5K	Buy	6,629 +3,748	+130%	+$4.09K	﹤0.01%	7349
2019 Q4	$3K	Buy	2,881 +698	+32%	+$544	﹤0.01%	7798
2019 Q3	$2K	Sell	2,183 -12	-0.5%	-$55	﹤0.01%	7783
2019 Q2	$18K	Buy	2,195 +12	+0.5%	+$81	﹤0.01%	6710
2019 Q1	$12K	Sell	2,183 -1,398	-39%	-$6.01K	﹤0.01%	6716
2018 Q4	$13K	Sell	3,581 -3,401	-49%	-$20.6K	﹤0.01%	7111
2018 Q3	$62K	Buy	6,982 +5,022	+256%	+$48.1K	﹤0.01%	5996
2018 Q2	$19K	Buy	+1,960	New	+$18.1K	﹤0.01%	6749
2018 Q1	–	Sell	-1,530	Closed	-$11K	–	8340
2017 Q4	$11K	Sell	1,530 -823	-35%	-$4.79K	﹤0.01%	6982
2017 Q3	$12K	Sell	2,353 -196	-8%	-$1.03K	﹤0.01%	6805
2017 Q2	$24K	Buy	+2,549	New	+$27.2K	﹤0.01%	6178

Other funds holding NTRP

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's NTRP Position: Q4 2020 in Review

UBS Group sold out of Neurotrope, Inc. Common (NTRP) in Q4 2020, closing a stake of 10,000 shares — an estimated $11K sold.

UBS Group first reported a position in NTRP in Q2 2017 and held it in 13 quarters. The position peaked at $62K in Q3 2018. 1 fund tracked by Wall St. Rank holds NTRP as of Q4 2020.

UBS Group reported no remaining Neurotrope, Inc. Common position as of Q4 2020 after selling out during the quarter.
UBS Group sold 10,000 Neurotrope, Inc. Common shares in Q4 2020, an estimated $11K.
UBS Group first reported a position in Neurotrope, Inc. Common in Q2 2017 and held it in 13 quarters.
UBS Group's Neurotrope, Inc. Common position peaked at $62K in Q3 2018.
1 fund tracked by Wall St. Rank held Neurotrope, Inc. Common as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.